![Valneva initiates heterologous booster trial of inactivated, COVID-19 vaccine candidate - Atlanpole Biotherapies : Atlanpole Biotherapies Valneva initiates heterologous booster trial of inactivated, COVID-19 vaccine candidate - Atlanpole Biotherapies : Atlanpole Biotherapies](https://www.atlanpolebiotherapies.eu/wp-content/uploads//2017/04/valneva.jpg)
Valneva initiates heterologous booster trial of inactivated, COVID-19 vaccine candidate - Atlanpole Biotherapies : Atlanpole Biotherapies
![Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001 - Valneva Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001 - Valneva](https://valneva.com/wp-content/uploads/2022/08/VLA2001-301_Homologous-Heterologous_Booster_Data.png)
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001 - Valneva
![Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials | Seeking Alpha Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289345741/image_1289345741.jpg?io=getty-c-crop-4-3)